PT3964510T - Forma cristalina do composto inibidor de wee1 e sua utilização - Google Patents
Forma cristalina do composto inibidor de wee1 e sua utilizaçãoInfo
- Publication number
- PT3964510T PT3964510T PT207989245T PT20798924T PT3964510T PT 3964510 T PT3964510 T PT 3964510T PT 207989245 T PT207989245 T PT 207989245T PT 20798924 T PT20798924 T PT 20798924T PT 3964510 T PT3964510 T PT 3964510T
- Authority
- PT
- Portugal
- Prior art keywords
- crystal form
- inhibitor compound
- wee1 inhibitor
- wee1
- compound
- Prior art date
Links
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3964510T true PT3964510T (pt) | 2024-07-29 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT207989245T PT3964510T (pt) | 2019-04-30 | 2020-04-30 | Forma cristalina do composto inibidor de wee1 e sua utilização |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220220120A1 (pt) |
| EP (1) | EP3964510B1 (pt) |
| JP (1) | JP2022530812A (pt) |
| CN (1) | CN113784968B (pt) |
| AU (1) | AU2020266956A1 (pt) |
| BR (1) | BR112021021230A8 (pt) |
| CA (1) | CA3138240A1 (pt) |
| DK (1) | DK3964510T3 (pt) |
| FI (1) | FI3964510T3 (pt) |
| IL (1) | IL287472A (pt) |
| LT (1) | LT3964510T (pt) |
| PL (1) | PL3964510T3 (pt) |
| PT (1) | PT3964510T (pt) |
| RS (1) | RS65747B1 (pt) |
| SG (1) | SG11202111315XA (pt) |
| WO (1) | WO2020221358A1 (pt) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| ES2442257T3 (es) * | 2006-10-27 | 2014-02-10 | Signal Pharmaceuticals Llc | Formas sólidas que comprenden 4-[9-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-ciclohexan-1-ol, sus composiciones y sus usos |
| US8198281B2 (en) | 2007-04-25 | 2012-06-12 | Merck Sharp & Dohme Corp. | Crystalline forms of dihydropyrazolopyrimidinone |
| JPWO2009054332A1 (ja) | 2007-10-23 | 2011-03-03 | 萬有製薬株式会社 | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| US8703779B2 (en) | 2009-09-15 | 2014-04-22 | Merck Sharp & Dohme Corp. | Preparation of crystalline forms of dihydropyrazolopyrimidinone |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| WO2013013031A1 (en) | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| CN104011049A (zh) | 2011-10-20 | 2014-08-27 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
| EP2817308B1 (en) | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| US11248006B2 (en) * | 2017-03-23 | 2022-02-15 | Shanghai De Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
| CN111344290B (zh) * | 2017-11-01 | 2023-12-01 | 无锡智康弘义生物科技有限公司 | 作为Wee1抑制剂的大环类化合物及其应用 |
| CN112955454A (zh) * | 2018-10-26 | 2021-06-11 | 石家庄智康弘仁新药开发有限公司 | 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用 |
-
2020
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 AU AU2020266956A patent/AU2020266956A1/en active Pending
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
- 2020-04-30 US US17/607,447 patent/US20220220120A1/en active Pending
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 JP JP2021564588A patent/JP2022530812A/ja active Pending
- 2020-04-30 CA CA3138240A patent/CA3138240A1/en active Pending
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh active Application Filing
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138240A1 (en) | 2020-11-05 |
| EP3964510A4 (en) | 2023-04-26 |
| FI3964510T3 (fi) | 2024-07-24 |
| WO2020221358A1 (zh) | 2020-11-05 |
| RS65747B1 (sr) | 2024-08-30 |
| AU2020266956A1 (en) | 2021-10-28 |
| SG11202111315XA (en) | 2021-11-29 |
| EP3964510B1 (en) | 2024-07-03 |
| LT3964510T (lt) | 2024-08-12 |
| CN113784968A (zh) | 2021-12-10 |
| JP2022530812A (ja) | 2022-07-01 |
| DK3964510T3 (da) | 2024-07-29 |
| IL287472A (en) | 2021-12-01 |
| US20220220120A1 (en) | 2022-07-14 |
| BR112021021230A8 (pt) | 2023-04-25 |
| PL3964510T3 (pl) | 2024-08-19 |
| BR112021021230A2 (pt) | 2021-12-21 |
| EP3964510A1 (en) | 2022-03-09 |
| CN113784968B (zh) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4056563A4 (en) | COMPOUND USED AS SHP2 INHIBITOR AND ITS USE | |
| ZA202106511B (en) | Jak inhibitor compound and use thereof | |
| EP3768267A4 (en) | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
| EP3851440A4 (en) | CYCLOPROPYLAMINE COMPOUND AS AN LSD1 INHIBITOR AND USE OF IT | |
| ZA202100923B (en) | Crystal form of lanosterol prodrug compound and application thereof | |
| EP3906233A4 (en) | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
| EP3906028A4 (en) | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| IL290106A (en) | A crystalline form of an atr inhibitor and its use | |
| IL276312A (en) | Use of Alkoxypyrazoles as nitrification inhibitors | |
| EP3766870A4 (en) | CRYSTAL OF A COMPOUND TO BE USED AS A KINASE C-MET INHIBITOR, PROCESS OF PREPARATION AND USE | |
| EP4071145A4 (en) | JAK INHIBITOR COMPOUND AND ITS USE | |
| EP3943496A4 (en) | WEE1 INHIBITOR AND METHOD OF MANUFACTURE AND USE THEREOF | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| EP4063366A4 (en) | CRYSTAL FORM OF NUCLEOPROTEIN INHIBITOR AND USE THEREOF | |
| EP4206201A4 (en) | CRYSTALLINE FORM OF AN AZETIDINE-SUBSTITUTED COMPOUND | |
| EP3738961A4 (en) | HETEROCYCLIC COMPOUND AS A CSF-1R INHIBITOR AND USE OF IT | |
| EP3774708A4 (en) | Foxm1 inhibitor compositions and methods of using the same | |
| ZA202101589B (en) | Crystal form of tri-cycle compound and application thereof | |
| IL287472A (en) | Crystalline form of wee1 inhibitory compound and use thereof | |
| EP3924335A4 (en) | ANTI-FIBROTIC NEU3 INHIBITOR COMPOUNDS AND METHODS OF USE | |
| EP3737945A4 (en) | NEW USE OF KIRREL2 AND A KIRREL2 INHIBITOR | |
| EP3845534A4 (en) | SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF | |
| EP3957634A4 (en) | CRYSTALLINE FORM OF SGLT INHIBITOR AND ITS APPLICATION | |
| EP4023648A4 (en) | CARCINOGENIC FUSIONED KINASE HIBITOR CRYSTAL AND APPLICATIONS THEREOF |